Integrated BioTherapeutics
Integrated BioTherapeutics, operating as IBT Bioservices, is a Rockville, Maryland-based preclinical CRO providing infectious-disease contract research services and specialized reagents for filoviruses, flaviviruses, and Staphylococcus aureus to biotech, pharmaceutical, academic, and government customers.
- Company typePrivate
- Founded2005
- HeadquartersRockville, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Integrated BioTherapeutics does
Integrated BioTherapeutics, operating commercially as IBT Bioservices since its February 2023 rebrand, is a privately held Contract Research Organization (CRO) headquartered in Rockville, Maryland. The company delivers preclinical and clinical research services alongside a catalog of specialized infectious-disease reagents. Its operations focus on three pathogen franchises: filoviruses (Ebola, Sudan, Marburg, Bundibugyo, Ravn), flaviviruses (Dengue, Zika, West Nile, Yellow Fever), and Staphylococcus aureus (including MRSA). Through its wholly owned subsidiary IBT Vaccines, the parent historically pursued internal vaccine development (most notably IBT-V02 for MRSA), but in February 2023 that R&D portfolio was spun off into AbVacc, Inc., leaving IBT Bioservices to concentrate on services.
The company operates a hybrid platform-plus-services model. Its technology stack includes VSV-based pseudovirus platforms enabling BSL-2 safety for highly pathogenic viral work, AG129 mouse models for flaviviruses, a validated Luminex multiplexed cytokine analysis platform (20+ years of team experience, 150+ projects supported), and an extensive catalog of recombinant proteins, monoclonal antibodies, pseudoviruses, and ELISA kits spanning filoviruses, flaviviruses, coronaviruses, alphaviruses, S. aureus toxins and superantigens, and influenza. Capacity includes pseudovirus neutralization assays running up to 100 plates per week, and services are delivered under GLP/GCLP/GMP compliance with ISO 9001 quality accreditation.
Revenue is generated through two primary streams: contract research services priced per quote based on project scope, and unit-priced reagent sales ($242-$1,137 per recombinant protein, $379-$758 per antibody) under NET30 terms. Customers span biotech and pharmaceutical companies, academic laboratories, and government agencies (NIH/NIAID, BARDA, DoD, USAMRIID). GTM motion is sales-led with direct outreach, a global network of 12+ distribution partners (Abcam, VWR, Fisher Scientific, Thomas Scientific, plus regional Asia/Europe distributors), industry-conference presence, and concierge program management for complex multi-year engagements. The company also benefits from substantial non-dilutive grant support — leadership has helped clients secure over $150M and has personally obtained over $100M in NIH/DoD funding.
Integrated BioTherapeutics firmographics
Firmographics- Name
- Integrated BioTherapeutics
- Legal name
- Integrated Biotherapeutics LLC
- Website
- https://ibtbioservices.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Integrated BioTherapeutics, operating as IBT Bioservices, is a Rockville, Maryland-based preclinical CRO providing infectious-disease contract research services and specialized reagents for filoviruses, flaviviruses, and Staphylococcus aureus to biotech, pharmaceutical, academic, and government customers.
- Ownership category
- akta.pro rank
Integrated BioTherapeutics industry classification
Industry- Product category
- Contract Research Organization (Preclinical CRO Services)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
- akta.pro secondary industry
- Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
Keywords
Where Integrated BioTherapeutics is headquartered
LocationHeadquarters
- HQ city
- Rockville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Integrated BioTherapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Contract Research Services: Fee-for-service preclinical and clinical testing services including in vitro assays, animal studies, assay development, and GxP-compliant testing. Revenue generated through project-based contracts with biotech/pharma companies, academic institutions, and government agencies.
- Reagent Sales: Sale of research reagents including recombinant proteins, antibodies, pseudoviruses, ELISA kits, and cell lines through direct online ordering and distribution partners. Products priced per unit with standard payment terms of NET30.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Recombinant proteins from $242 to $1,137 per unit depending on product and size |
| Unit Pricing | Pay-as-you-go | Antibodies from $379 to $758 per unit |
| Other | Multi-year contract | CRO services - quote-based pricing |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Integrated BioTherapeutics product offering
Product offeringCore offering
Integrated BioTherapeutics, operating as IBT Bioservices, is a Contract Research Organization that provides preclinical and clinical research services, including in vitro assays (neutralization, ELISA, Luminex, qPCR), in vivo animal studies, GxP-compliant testing, and concierge program management for infectious disease vaccine and therapeutic developers. The company also manufactures and sells a catalog of specialized research reagents—recombinant proteins, antibodies, pseudoviruses, virus-like particles, ELISA kits, and cell lines—targeting filoviruses, flaviviruses, S. aureus, influenza, and other pathogens.
Product overview
IBT Bioservices is a Contract Research Organization (CRO) providing preclinical and clinical research services along with specialized research reagents for infectious disease research. The company operates under a platform-plus-services model, offering a comprehensive catalog of reagents (recombinant proteins, antibodies, pseudoviruses, ELISA kits) for pathogens including filoviruses (Ebola, Marburg, Sudan, Bundibugyo), flaviviruses (Dengue, Zika, West Nile), Staphylococcus aureus, and influenza, complemented by fee-for-service laboratory testing including in vitro assays (neutralization, ELISA, Luminex, qPCR), in vivo animal models, GxP compliance testing, and concierge program management. The company rebranded from Integrated Biotherapeutics in February 2023, spinning off its vaccines R&D into AbVacc, Inc.
Differentiator
Problem solved
Functional benefit
Products and services
- IBT Bioservices Reagents Catalog of research reagents including recombinant proteins, primary antibodies, pseudoviruses, virus-like particles, vaccine adjuvants, ELISA kits, and cell lines for infectious disease research targeting filoviruses, flaviviruses, coronaviruses, alphaviruses, Staphylococcus aureus, and other pathogens. Sold per-unit through the online storefront and distribution partners.
- In Vitro Assays Fee-for-service in vitro testing including antiviral assays (CPE, HAI, microneutralization, PRNT, pseudovirus neutralization, yield reduction), bacterial assays, ELISA, functional assays (Western Blot), immunoassay, Luminex cytokine assays, flow cytometry, viability assays (Cell-TiterGLO, cytotoxicity), qPCR, SDS-PAGE, and custom antibody production. For biotech, pharma, academic, and government clients developing vaccines and therapeutics.
- Animal Services Preclinical in vivo testing services including AG129 mouse models, custom animal models, dermatology models, bacterial efficacy models (E. coli ETEC, S. aureus, Streptococcus pneumoniae), viral efficacy models (Chikungunya, Dengue, Influenza, RSV, Zika), vaccine adjuvant screening, biodistribution studies, and vivarium rental. For vaccine and therapeutic developers needing regulated preclinical data.
- GxP Services GLP (Good Laboratory Practice), GCLP, and GMP (Good Manufacturing Practice) compliant testing services for regulatory submissions, including clinical assay strategy and release assays. Laboratory accreditation through Pharmaceutical Laboratory Accreditation (PJLA). For sponsors needing regulatory-grade preclinical and clinical data.
- Concierge Services
Quantifiable outcome
- Supported clients in securing over $150M in cumulative grant funding
- +4 more outcomes
Companies that use Integrated BioTherapeutics
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
Integrated BioTherapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Integrated BioTherapeutics partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered standard, regional and major.
- Thomas ScientificstandardDistribution partner for IBT Bioservices reagents in the USA market.
- AbcamstandardDistribution partner for IBT Bioservices reagents in Europe and USA markets.
- VWRstandardDistribution partner for IBT Bioservices research reagents.
- Fisher ScientificstandardDistribution partner for IBT Bioservices products.
- Mayflower BiosciencesstandardAuthorized distributor for IBT Bioservices reagents in the USA.
- USBiologicalstandardDistribution partner for IBT Bioservices products.
- Clementia BiotechregionalDistribution partner covering India and Asia markets.
- GentaurstandardDistribution partner for IBT Bioservices products.
- Tokyo Future StyleregionalDistribution partner for IBT Bioservices products.
- EliteImmunestandardDistribution partner for IBT Bioservices products.
- HolzelregionalDistribution partner covering European markets.
- InterLabstandardDistribution partner for IBT Bioservices products.
- AbVacc, Inc.majorSpin-off company created from IBT Bioservices' pioneering R&D portfolio of vaccines and therapeutics. IBT Bioservices repositioned its vaccine and therapeutic pipeline into AbVacc to intensify focus on CRO services while AbVacc advances the product pipeline.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
Integrated BioTherapeutics competitors and assessment
Company assessmentBroad incumbents
- Battelle: Large applied science and CRO with biodefense and infectious disease research programs (including prior CDC/NIAID biodefense contracts), competing with IBT for federal biodefense and public health laboratory work.
- Eurofins Viracor BioPharma: Specialty infectious disease and immunology reference laboratory offering clinical trial and preclinical testing services for pharma and biotech, overlapping IBT's immunoassay, neutralization, and biopharma testing offerings at greater scale.
- GenScript: Much larger CRO/CDMO spanning gene synthesis, protein and antibody production, and cell therapy services; competes with IBT on recombinant protein, antibody, and cell-based assay work but at substantially greater scale and global footprint.
- Charles River Laboratories: Global preclinical CRO with established infectious disease and vaccine testing services; competes with IBT for biodefense and pharma vaccine preclinical work, leveraging far larger scale, BSL-3 footprint, and integrated service portfolio.
Direct peers
- LakePharma (Curia): Biologics-focused preclinical CRO with antibody engineering, cell line, and protein production services, directly overlapping IBT's custom antibody, in vitro assay, and recombinant protein capabilities for therapeutic developers.
- ZeptoMetrix: Infectious disease reagents and controls provider (viruses, bacteria, NATtrol controls), competing with IBT's pseudovirus and viral antigen reagents in clinical and reference lab channels.
- ProSci: Custom antibody and reagent company of comparable size, serving infectious disease and immunology researchers with custom antibody production services that overlap IBT's antibody, ELISA, and recombinant protein offerings.
- Bioqual (Bionova Scientific): Preclinical CRO specializing in infectious disease, HIV, and emerging pathogen studies with BSL-3 capacity, mirroring IBT's infectious disease preclinical testing, in vivo models, and biodefense customer base.
- ATCC: Global biological reagents and reference materials supplier (cell lines, viruses, proteins), with a similar mission of providing standardized infectious disease reagents to academic, government, and biopharma customers.
- Sino Biological: Recombinant protein, antibody, and reagent manufacturer for infectious disease research, overlapping IBT's reagent catalog across viruses (filoviruses, flaviviruses, coronaviruses) and offering a comparable e-commerce plus CRO-adjacent offering.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Integrated BioTherapeutics social profiles
Digital presenceIntegrated BioTherapeutics compliance and trust
Trust signalCompliance2 records
Integrated BioTherapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Integrated BioTherapeutics leadership team
Management profileNumber of profiles
Profiles3 records
Integrated BioTherapeutics subsidiaries and ownership
Company hierarchySubsidiaries2 records
Integrated BioTherapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Integrated BioTherapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Integrated BioTherapeutics
What does Integrated BioTherapeutics do?
Integrated BioTherapeutics, operating as IBT Bioservices, is a Contract Research Organization that provides preclinical and clinical research services, including in vitro assays (neutralization, ELISA, Luminex, qPCR), in vivo animal studies, GxP-compliant testing, and concierge program management for infectious disease vaccine and therapeutic developers. The company also manufactures and sells a catalog of specialized research reagents—recombinant proteins, antibodies, pseudoviruses, virus-like particles, ELISA kits, and cell lines—targeting filoviruses, flaviviruses, S. aureus, influenza, and other pathogens.
Is Integrated BioTherapeutics a public or private company?
Integrated BioTherapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Integrated BioTherapeutics founded?
Integrated BioTherapeutics was founded in 2005. It employs 11 to 50 people.
Where is Integrated BioTherapeutics based?
Integrated BioTherapeutics is headquartered in Rockville, United States, in the North America region.
How does Integrated BioTherapeutics make money?
Two revenue lines are on record. Contract Research Services are the primary driver. The others are reagent Sales.
Who are Integrated BioTherapeutics's main competitors?
Broad incumbents on record are Battelle, Eurofins Viracor BioPharma, GenScript and Charles River Laboratories. Direct peers are LakePharma (Curia), ZeptoMetrix, ProSci, Bioqual (Bionova Scientific), ATCC and Sino Biological.
Does Integrated BioTherapeutics have an API?
No public API is recorded for Integrated BioTherapeutics.
What industry is Integrated BioTherapeutics in?
Integrated BioTherapeutics's product category is Contract Research Organization (Preclinical CRO Services). Its primary akta.pro industry code is HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry), with a secondary code of HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes). Its NAICS code is 541714 and its SIC code is 8731.